Understanding the underlying mechanism of steroid-resistant asthma
Asthma affects more than 300 million people worldwide, and while many can control their symptoms with inhaled steroid medications, about 10% develop a more severe form that does not respond well to these treatments. This steroid-resistant asthma is one of the most difficult forms of the disease to manage.
This report delves into the complexities of steroid-resistant asthma, a severe form of the disease that defies common treatment methods. Asthma, a condition that plagues over 300 million individuals globally, is typically manageable with inhaled steroid medications; however, around 10% of sufferers experience a more resistant form of the disease. Dr. David Corry, a leading researcher in the field, emphasized the need to uncover new therapeutic avenues to aid these patients.
To unearth the underlying causes, the researchers developed a specialized mouse model that mirrored the human condition. They discovered that exposing these mice to the Aspergillus niger fungus led to asthma-like symptoms, including airway inflammation and increased sensitivity. Notably, administering steroids alleviated some inflammation but failed to rectify the airway dysfunction responsible for breathing difficulties.
Adding small quantities of bacterial substances known as lipopolysaccharides (LPS) exacerbated the disease further, creating a form of asthma akin to severe human cases.
Further investigation unveiled the role of fibrinogen cleavage products, or cryptokines, in steroid resistance. Fibrinogen, a clotting protein, transforms into fibrin within the lungs, forming obstructions that impede airflow. When fungal enzymes break down fibrin, cryptokines are generated, activating TLR4, a receptor that exacerbates airway hyperresponsiveness.
Surprisingly, steroids did not inhibit this pathway activation. Furthermore, airway epithelial cells, lining the respiratory tract, produce fibrinogen and prothrombin, triggering a self-perpetuating cycle of protein production. This cycle likely worsens airway disease over time.
In conclusion, the research indicates that severe steroid-resistant asthma may stem from fungal activity, bacterial products like LPS, and clotting-related proteins that engage TLR4, triggering a self-reinforcing cycle of airway dysfunction. These insights suggest that therapies targeting these pathways could offer new hope for patients with this challenging condition.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
